Strata Critical Medical (SRTA) Q3 2024 earnings summary

Executive summary

• Achieved positive trailing twelve-month Passenger Segment Adjusted EBITDA over a year ahead of prior guidance, driven by margin expansion and cost discipline in both passenger and medical segments.

• Q3 2024 revenue grew 5% year-over-year to $74.9M, with strong Medical segment growth and improved margins, but a net loss of $2.0M due to non-cash warrant liability income decrease.

• Adjusted EBITDA rose to $4.2M in Q3 2024, up from $0.8M in Q3 2023, with strong conversion to $6.4M operating cash flow and $3.7M free cash flow before aircraft acquisitions.

• Strategic focus on profitable growth included exiting unprofitable Canadian operations, restructuring European business, and expanding Medical segment through acquisitions and alliances.

• Formed a strategic alliance with OrganOx to enhance rapid deployment of organ perfusion devices, supporting Medical segment growth.

Financial highlights

• Q3 2024 total revenue: $74.9M (up 5% YoY); Medical revenue: $36.1M (up 7.8% YoY); Passenger revenue: $38.8M (up 2% YoY).

• Q3 2024 Flight Profit: $19.8M (up 27% YoY); Flight Margin: 26.5% (up from 21.8%).

• Adjusted EBITDA: $4.2M (margin 5.6%–6%); net loss: $2.0M for Q3 2024.

• Gross margin improved to 19.3% in Q3 2024 from 14.1% a year ago.

• Ended Q3 2024 with $136.3M in cash and short-term investments, and no debt.

Outlook and guidance

• Reaffirmed 2024 revenue guidance of $240M–$250M and positive Adjusted EBITDA.

• 2025 guidance: double-digit Medical revenue growth, Passenger revenue of $85M–$95M, and positive free cash flow before aircraft acquisitions.

• Medical Segment Adjusted EBITDA margin expected to reach ~15% in 2025, with long-term target in the high teens.

• Sufficient liquidity to meet operational needs for at least the next 12 months.